By positively affecting these cardiac parameters, SGLT2 inhibitors facilitate better symptom management and reduce the recurrence of heart failure, thereby minimizing the risk of long-term complications such as myocardial infarction. The gene discussed is SLC5A2; the disease is heart failure.